These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


Pubmed for Handhelds

PUBMED FOR HANDHELDS

Journal Abstract Search

644 related items for PubMed ID: 19489655

  • 1. Dapsone 5% gel: a review of its efficacy and safety in the treatment of acne vulgaris.
    Stotland M, Shalita AR, Kissling RF.
    Am J Clin Dermatol; 2009; 10(4):221-7. PubMed ID: 19489655
    [Abstract] [Full Text] [Related]

  • 2. An evaluation of dapsone gel 5% in the treatment of acne vulgaris.
    Pickert A, Raimer S.
    Expert Opin Pharmacother; 2009 Jun; 10(9):1515-21. PubMed ID: 19505219
    [Abstract] [Full Text] [Related]

  • 3. Aczone, a topical gel formulation of the antibacterial, anti-inflammatory dapsone for the treatment of acne.
    Scheinfeld N.
    Curr Opin Investig Drugs; 2009 May; 10(5):474-81. PubMed ID: 19431080
    [Abstract] [Full Text] [Related]

  • 4. Two randomized studies demonstrate the efficacy and safety of dapsone gel, 5% for the treatment of acne vulgaris.
    Draelos ZD, Carter E, Maloney JM, Elewski B, Poulin Y, Lynde C, Garrett S, United States/Canada Dapsone Gel Study Group.
    J Am Acad Dermatol; 2007 Mar; 56(3):439.e1-10. PubMed ID: 17208334
    [Abstract] [Full Text] [Related]

  • 5. Hematologic safety of dapsone gel, 5%, for topical treatment of acne vulgaris.
    Piette WW, Taylor S, Pariser D, Jarratt M, Sheth P, Wilson D.
    Arch Dermatol; 2008 Dec; 144(12):1564-70. PubMed ID: 19075138
    [Abstract] [Full Text] [Related]

  • 6. Dapsone gel 5% for the treatment of acne vulgaris: safety and efficacy of long-term (1 year) treatment.
    Lucky AW, Maloney JM, Roberts J, Taylor S, Jones T, Ling M, Garrett S, Dapsone Gel Long-Term Safety Study Group.
    J Drugs Dermatol; 2007 Oct; 6(10):981-7. PubMed ID: 17966175
    [Abstract] [Full Text] [Related]

  • 7. Is topical dapsone safe in glucose-6-phosphate dehydrogenase-deficient and sulfonamide-allergic patients?
    Webster GF.
    J Drugs Dermatol; 2010 May; 9(5):532-6. PubMed ID: 20480797
    [Abstract] [Full Text] [Related]

  • 8. Pharmacokinetics of dapsone gel, 5% for the treatment of acne vulgaris.
    Thiboutot DM, Willmer J, Sharata H, Halder R, Garrett S.
    Clin Pharmacokinet; 2007 May; 46(8):697-712. PubMed ID: 17655376
    [Abstract] [Full Text] [Related]

  • 9. Harnessing the anti-inflammatory effects of topical dapsone for management of acne.
    Kircik LH.
    J Drugs Dermatol; 2010 Jun; 9(6):667-71. PubMed ID: 20645528
    [Abstract] [Full Text] [Related]

  • 10. Dapsone 7.5% Gel: A Review in Acne Vulgaris.
    Al-Salama ZT, Deeks ED.
    Am J Clin Dermatol; 2017 Feb; 18(1):139-145. PubMed ID: 28005194
    [Abstract] [Full Text] [Related]

  • 11. Dapsone 5% gel: a new option in topical therapy for acne.
    Tan J.
    Skin Therapy Lett; 2012 Sep; 17(8):1-3. PubMed ID: 22949131
    [Abstract] [Full Text] [Related]

  • 12. Efficacy and safety of dapsone gel 5% for the treatment of acne vulgaris in adolescents.
    Raimer S, Maloney JM, Bourcier M, Wilson D, Papp K, Siegfried E, Garrett S, United States/Canada Dapsone Gel Study Group.
    Cutis; 2008 Feb; 81(2):171-8. PubMed ID: 18441772
    [Abstract] [Full Text] [Related]

  • 13. Effects of tazarotene 0.1 % cream in the treatment of facial acne vulgaris: pooled results from two multicenter, double-blind, randomized, vehicle-controlled, parallel-group trials.
    Shalita AR, Berson DS, Thiboutot DM, Leyden JJ, Parizadeh D, Sefton J, Walker PS, Gibson JR, Tazarotene Cream in Acne Clinical Study Investigator Group.
    Clin Ther; 2004 Nov; 26(11):1865-73. PubMed ID: 15639698
    [Abstract] [Full Text] [Related]

  • 14. Efficacy and Safety of Once-Daily Dapsone Gel, 7.5% for Treatment of Adolescents and Adults With Acne Vulgaris: First of Two Identically Designed, Large, Multicenter, Randomized, Vehicle-controlled Trials.
    Stein Gold LF, Jarratt MT, Bucko AD, Grekin SK, Berlin JM, Bukhalo M, Weiss JS, Berk DR, Chang-Lin JE, Lin V, Kaoukhov A.
    J Drugs Dermatol; 2016 May 01; 15(5):553-61. PubMed ID: 27168264
    [Abstract] [Full Text] [Related]

  • 15. Clinical evidence for the role of a topical anti-inflammatory agent in comedonal acne: findings from a randomized study of dapsone gel 5% in combination with tazarotene cream 0.1% in patients with acne vulgaris.
    Tanghetti E, Dhawan S, Green L, Ling M, Downie J, Germain MA, Kasteler JS, Kircik L, Oefelein MG, Draelos Z.
    J Drugs Dermatol; 2011 Jul 01; 10(7):783-92. PubMed ID: 21720661
    [Abstract] [Full Text] [Related]

  • 16. Safety and Pharmacokinetics of Once-Daily Dapsone Gel, 7.5% in Patients With Moderate Acne Vulgaris.
    Jarratt MT, Jones TM, Chang-Lin JE, Tong W, Berk DR, Lin V, Kaoukhov A.
    J Drugs Dermatol; 2016 Oct 01; 15(10):1250-1259. PubMed ID: 27741344
    [Abstract] [Full Text] [Related]

  • 17. Newer topical therapies for the treatment of acne vulgaris.
    Del Rosso JQ.
    Cutis; 2007 Nov 01; 80(5):400-10. PubMed ID: 18189027
    [Abstract] [Full Text] [Related]

  • 18. The efficacy and tolerability of dapsone 5% gel in female vs male patients with facial acne vulgaris: gender as a clinically relevant outcome variable.
    Tanghetti E, Harper JC, Oefelein MG.
    J Drugs Dermatol; 2012 Dec 01; 11(12):1417-21. PubMed ID: 23377510
    [Abstract] [Full Text] [Related]

  • 19. Efficacy and Safety of Once-Daily Dapsone Gel, 7.5% for Treatment of Adolescents and Adults With Acne Vulgaris: Second of Two Identically Designed, Large, Multicenter, Randomized, Vehicle-Controlled Trials.
    Eichenfield LF, Lain T, Frankel EH, Jones TM, Chang-Lin JE, Berk DR, Ruan S, Kaoukhov A.
    J Drugs Dermatol; 2016 Aug 01; 15(8):962-9. PubMed ID: 27537997
    [Abstract] [Full Text] [Related]

  • 20. Use of Dapsone 5% Gel as Maintenance Treatment of Acne Vulgaris Following Completion of Oral Doxycycline and Dapsone 5% Gel Combination Treatment.
    Kircik LH.
    J Drugs Dermatol; 2016 Feb 01; 15(2):191-5. PubMed ID: 26885787
    [Abstract] [Full Text] [Related]

    Page: [Next] [New Search]
    of 33.